Advanced search
Publication Cover
Pharmacogenomics Volume 7, 2006 - Issue 7
Submit an article Journal homepage
924
Views
0
CrossRef citations to date
0
Altmetric
Review

Therapeutic Targets and Biomarkers Identified in Cancer Choline Phospholipid Metabolism

Kristine Glunde1 The Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, 720 Rutland Avenue, 212 Traylor Building Baltimore, MD21205, USA. Tel: +1 410 614 2705; [email protected]View further author information
&
Natalie J Serkova2 Department of Anesthesiology, Biomedical MRS/MRI Cancer Center Core, University of Colorado Health Sciences Center, Denver, CO80262, USA.View further author information
Pages 1109-1123 | Published online: 20 Oct 2006

Bibliography

  • Podo F : Tumour phospholipid metabolism.NMR Biomed.12(7) , 413–439 (1999).
  • Ackerstaff E , GlundeK, BhujwallaZM: Choline phospholipid metabolism: a target in cancer cells?J. Cell Biochem.90(3) , 525–533 (2003).
  • Gillies RJ , BhujwallaZM, EvelhochJ et al.: Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia2(1–2) , 139–151 (2000).
  • Evelhoch JL , GilliesRJ, KarczmarGS et al.: Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia2(1–2) , 152–165 (2000).
  • Griffin JL , ShockcorJP: Metabolic profiles of cancer cells.Nat. Rev. Cancer4(7) , 551–561 (2004).
  • Negendank W : Studies of human tumors by MRS: a review.NMR Biomed.5(5) , 303–324 (1992).
  • Ronen SM , LeachMO: Imaging biochemistry: applications to breast cancer.Breast Cancer Res.3(1) , 36–40 (2001).
  • Franks SE , SmithMR, Arias-MendozaF et al.: Phosphomonoester concentrations differ between chronic lymphocytic leukemia cells and normal human lymphocytes. Leuk. Res.26(10) , 919–926 (2002).
  • Aboagye EO , BhujwallaZM: Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells.Cancer Res.59(1) , 80–84 (1999).
  • Iorio E , MezzanzanicaD, AlbertiP et al.: Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res.65(20) , 9369–9376 (2005).
  • Jacobs MA , BarkerPB, BottomleyPA, BhujwallaZ, BluemkeDB: Proton MR spectroscoptic imaging of human breast cancer:a preliminary study.J. Magn. Reson. Imaging19(1) , 68–75 (2004).
  • Arias-Mendoza F , PayneGS, ZakianKL et al.: In vivo31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. NMR Biomed.19(4) , 504–512 (2006).
  • Albers MJ , KriegerMD, Gonzalez-GomezI et al.: Proton-decoupled 31P MRS in untreated pediatric brain tumors. Magn. Reson. Med.53(1) , 22–29 (2005).
  • Barker PB , GlicksonJD, BryanRN: In vivo magnetic resonance spectroscopy of human brain tumors.Top. Magn. Reson. Imaging.5(1) , 32–45 (1993).
  • Pouwels PJW , FrahmJ: Regional metabolite concentrations in human brain as determined by quantitative localized proton MRS.Magn. Reson. Med.39(1) , 53–60 (1998).
  • Ross B , MichaelisT: Clinical applications of magnetic resonance spectroscopy.Magn. Reson. Q.10(4) , 191–247 (1994).
  • Chang L , McBrideD, MillerBL et al.: Localized in vivo1H magnetic resonance spectroscopy and in vitro analyses of heterogeneous brain tumors. J. Neuroimaging5(3) , 157–163 (1995).
  • Tzika AA , ChengLL, GoumnerovaL et al.: Biochemical characterization of pediatric brain tumors by using in vivo and ex vivo magnetic resonance spectroscopy. J. Neurosurg.96(6) , 1023–1031 (2002).
  • Nelson SJ : Analysis of volume MRI and MR spectroscopic imaging data for the evaluation of patients with brain tumors.Magn. Reson. Med.46(2) , 228–239 (2001).
  • Howe FA , BartonSJ, CudlipSA et al.: Metabolic profiles of human brain tumors using quantitative in vivo1H magnetic resonance spectroscopy. Magn. Reson. Med.49(2) , 223–232 (2003).
  • Murphy M , LoosemoreA, CliftonAG et al.: The contribution of proton magnetic resonance spectroscopy (1H MRS) to clinical brain tumour diagnosis. Br. J. Neurosurg.16(4) , 329–334 (2002).
  • Lindskog M , SpengerC, KlasonT et al.: Proton magnetic resonance spectroscopy in neuroblastoma: current status, prospects and limitations. Cancer Lett.228(1–2) , 247–255 (2005).
  • Jenkinson MD , SmithTS, JoyceK et al.: MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology64(12) , 2085–2089 (2005).
  • Jeun SS , KimMC, KimBS et al.: Assessment of malignancy in gliomas by 3T 1H MR spectroscopy. Clin. Imaging29(1) , 10–15 (2005).
  • McKnight TR : Proton magnetic resonance spectroscopic evaluation of brain tumor metabolism.Semin. Oncol.31(5) , 605–617 (2004).
  • Narayan P , KurhanewiczJ: Magnetic resonance spectroscopy in prostate disease: diagnostic possibilities and future developments.Prostate Suppl.4 , 43–50 (1992).
  • Schick F , BongersH, KurzS et al.: Localized proton MR spectroscopy of citrate in vitro and of the human prostate in vivo at 1.5 T. Magn. Reson. Med.29(1) , 38–43 (1993).
  • Kurhanewicz J , VigneronDB, HricakH et al.: Three-dimensional 1H MR spectroscopic imaging of the in situ human prostate with high (0.24–0.7-cm3) spatial resolution. Radiology198(3) , 795–805 (1996).
  • Menard C , SmithIC, SomorjaiRL et al.: Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int. J. Radiat. Oncol. Biol. Phys.50(2) , 317–323 (2001).
  • Jagannathan NR , SinghM, GovindarajuV et al.: Volume localized in vivo proton MR spectroscopy of breast carcinoma: variation of water-fat ratio in patients receiving chemotherapy. NMR Biomed.11(8) , 414–422 (1998).
  • Roebuck JR , CecilKM, SchnallMD, LenkinskiRE: Human breast lesions: Characterization with proton MR spectroscopy.Radiology209(1) , 269–275 (1998).
  • Yeung DK , CheungHS, TseGM: Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy – initial results.Radiology220(1) , 40–46 (2001).
  • Bolan PJ , MeisamyS, BakerEH et al.: In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn. Reson. Med.50(6) , 1134–1143 (2003).
  • Meisamy S , BolanPJ, BakerEH et al.: Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of observer performance study at 4.0 T. Radiology236(2) , 465–475 (2005).
  • Stanwell P , GluchL, ClarkD et al.: Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5 T. Eur. Radiol.15(5) , 1037–1043 (2005).
  • Baik HM , SuMY, YuH, NalciogluO, MehtaR: Quantification of choline-containing compounds in malignant breast tumors by (1)H MR spectroscopy using water as an internal reference at 1.5 T.Magma19(2) , 96–104 (2006).
  • Lehnhardt FG , BockC, RohnG, Ernestus RI, Hoehn M: Metabolic differences between primary and recurrent human brain tumors: a 1H NMR spectroscopic investigation. NMR Biomed.18(6) , 371–382 (2005).
  • Mountford CE , SomorjaiRL, MalychaP et al.: Diagnosis and prognosis of breast cancer by magnetic resonance spectroscopy of fine-needle aspirates analysed using a statistical classification strategy. Br. J. Surg.88(9) , 1234–1240 (2001).
  • Swanson MG , VigneronDB, TabatabaiZL et al.: Proton HR-MAS spectroscopy and quantitative pathologic analysis of M RI/3D-MRSI-targeted postsurgical prostate tissues. Magn. Reson. Med.50(5) , 944–954 (2003).
  • Millis K , WeybrightP, CampbellN et al.: Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy. Magn. Reson. Med.41(2) , 257–267 (1999).
  • Zakian KL , Shukla-DaveA, MeyersP et al.: Identification of prognostic markers in bone sarcomas using proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res.63(24) , 9042–9047 (2003).
  • Nelson SJ , GravesE, PirzkallA et al.:In vivo molecular imaging for planning radiation therapy of gliomas: an application of 1H MRSI. J. Magn. Reson. Imaging16(4) , 464–476 (2002).
  • Zaider M , ZelefskyMJ, LeeEK et al.: Treatment planning for prostate implants using magnetic-resonance spectroscopy imaging. Int. J. Radiat. Oncol. Biol. Phys.47(4) , 1085–1096 (2000).
  • Law M , ChaS, KnoppEA et al.: High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology222(3) , 715–721 (2002).
  • Meisamy S , BolanPJ, BakerEH et al.: Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo1H MR spectroscopy – a pilot study at 4 T. Radiology233(2) , 424–431 (2004).
  • Manton DJ , ChaturvediA, HubbardA et al.: Neoadjuvant chemotherapy in breast cancer: early response prediction with quantitative MR imaging and spectroscopy. Br. J. Cancer94(3) , 427–435 (2006).
  • Kurhanewicz J , VigneronDB, NelsonSJ: Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer.Neoplasia2(1–2) , 166–189 (2000).
  • Mueller-Lisse UG , SwansonMG, Vigneron DB et al.: Time-dependent effects of hormone-deprivation therapy on prostate metabolism as detected by combined magnetic resonance imaging and 3D magnetic resonance spectroscopic imaging. Magn. Reson. Med.46(1) , 49–57 (2001).
  • Kurhanewicz J , VigneronDB, HricakH et al.: Prostate cancer: metabolic response to cryosurgery as detected with 3D 1H MR spectroscopic imaging. Radiology200(2) , 489–496 (1996).
  • Ramirez de Molina A , Rodriguez-Gonzalez A, Gutierrez R et al.: Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem. Biophys. Res. Commun.296(3) , 580–583 (2002).
  • Ramirez de Molina A , GutierrezR, Ramos MA et al.: Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene21(27) , 4317–4322 (2002).
  • Nakagami K , UchidaT, OhwadaS, KoibuchiY, MorishitaY: Increased choline kinase activity in 1,2-dimethylhydrazine-induced rat colon cancer.Jpn. J. Cancer Res.90(11) , 1212–1217 (1999).
  • Nakagami K , UchidaT, OhwadaS et al.: Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn. J. Cancer Res.90(4) , 419–424 (1999).
  • Glunde K , JieC, BhujwallaZM: Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.Cancer Res.64(12) , 4270–4276 (2004).
  • Glunde K , RamanV, MoriN, Bhujwalla ZM:RNA interference-mediated choline kinase suppression in breast cancer cells induces differentiation and reduces proliferation. Cancer Res.65(23) , 11034–11043 (2005).
  • Ramirez de Molina A , Rodriguez-Gonzalez A, Penalva V, Lucas L, Lacal JC: Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells. Biochem. Biophys. Res. Commun.285(4) , 873–879 (2001).
  • Ramirez de Molina A , PenalvaV, LucasL, LacalJC: Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K.Oncogene21(6) , 937–946 (2002).
  • Ferretti A , PodoF, CarpinelliG et al.: Detection of neutral active phosphatidylcholine-specific phospholipase C in Friend leukemia cells before and after erythroid differentiation. Anticancer Res.13(6A) , 2309–2317 (1993).
  • Podo F , FerrettiA, KnijnA et al.: Detection of phosphatidylcholine-specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies. Anticancer Res.16(3B) , 1399–1412 (1996).
  • Wu X , LuH, ZhouL, HuangY, ChenH: Changes of phosphatidylcholine-specific phospholipase C in hepatocarcinogenesis and in the proliferation and differentiation of rat liver cancer cells.Cell Biol. Int.21(6) , 375–381 (1997).
  • Ramoni C , SpadaroF, BarlettaB, Dupuis ML, Podo F: Phosphatidylcholine-specific phospholipase C in mitogen-stimulated fibroblasts. Exp. Cell Res.299(2) , 370–382 (2004).
  • Momchilova A , MarkovskaT, PankovR: Ha-ras-transformation alters the metabolism of phosphatidylethanolamine and phosphatidylcholine in NIH 3T3 fibroblasts.Cell Biol. Int.23(9) , 603–610 (1999).
  • Teegarden D , TaparowskyEJ, KentC: Altered phosphatidylcholine metabolism in C3H10T1/2 cells transfected with the Harvey-ras oncogene.J. Biol. Chem.265(11) , 6042–6047 (1990).
  • Cuadrado A , CarneroA, DolfiF, JimenezB, LacalJC: Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors.Oncogene8(11) , 2959–2968 (1993).
  • Chung T , HuangJS, MukherjeeJJ, Crilly KS, Kiss Z: Expression of human choline kinase in NIH 3T3 fibroblasts increases the mitogenic potential of insulin and insulin-like growth factor I. Cell Signal12(5) , 279–288 (2000).
  • Katz-Brull R , DeganiH: Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method.Anticancer Res.16(3B) , 1375–1380 (1996).
  • Katz-Brull R , SegerD, Rivenson-SegalD, RushkinE, DeganiH: Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis.Cancer Res.62(7) , 1966–1970 (2002).
  • Foster DA , XuL: Phospholipase D in cell proliferation and cancer.Mol. Cancer Res.1(11) , 789–800 (2003).
  • del Peso L , LucasL, EsteveP, LacalJC: Activation of phospholipase D by growth factors and oncogenes in murine fibroblasts follow alternative but cross-talking pathways.Biochem. J.322(Pt 2) , 519–528 (1997).
  • Balsinde J , WinsteadMV, DennisEA: Phospholipase A(2) regulation of arachidonic acid mobilization.FEBS Lett.531(1) , 2–6 (2002).
  • Laye JP , GillJH: Phospholipase A2 expression in tumours: a target for therapeutic intervention?Drug Discov. Today8(15) , 710–716 (2003).
  • Bhujwalla ZM , AboagyeEO, GilliesRJ et al.: Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro. Magn. Reson. Med.41(5) , 897–903 (1999).
  • Ronen SM , JacksonLE, BelouecheM, LeachMO: Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in NIH 3T3 cells.Br. J. Cancer84(5) , 691–696 (2001).
  • Ratnam S , KentC: Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines.Arch. Biochem. Biophys.323(2) , 313–322 (1995).
  • Lucas L , PenalvaV, Ramirez de Molina A, Del Peso L, Lacal JC: Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1. Int. J. Oncol.21(3) , 477–485 (2002).
  • Hernandez-Alcoceba R , SanigerL, Campos J et al.: Choline kinase inhibitors as a novel approach for antiproliferative drug design. Oncogene15(19) , 2289–2301 (1997).
  • Rodriguez-Gonzalez A , de Molina AR, Fernandez F et al.: Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene22(55) , 8803–8812 (2003).
  • Hernandez-Alcoceba R , FernandezF, Lacal JC: In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery. Cancer Res.59(13) , 3112–3118 (1999).
  • Al-Saffar NM , TroyH, Ramirez de Molina A et al.: Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of the choline kinase inhibitor MN58b in human carcinoma models. Cancer Res.66(1) , 427–434 (2006).
  • Lacal JC : Choline kinase: a novel target for antitumor drugs.IDrugs4(4) , 419–426 (2001).
  • Rodriguez-Gonzalez A , Ramirez de Molina A, Benitez-Rajal J, Lacal JC: Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets. Prog. Cell Cycle Res,.5 , 191–201 (2003).
  • Steed PM , ChowAH: Intracellular signaling by phospholipase D as a therapeutic target.Curr. Pharm. Biotechnol.2(3) , 241–256 (2001).
  • Pai JK , FrankEA, BloodC, ChuM: Novel ketoepoxides block phospholipase D activation and tumor cell invasion.Anticancer Drug Des.9(4) , 363–372 (1994).
  • Workman P , AboagyeEO, ChungYL et al.: Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-testing clinical trials of innovative therapies. J. Natl Cancer Inst.98(9) , 580–598 (2006).
  • Weybright P , SundgrenPC, MalyP et al.: Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am. J. Roentgenol.185(6) , 1471–1476 (2005).
  • Balmaceda C , CritchellD, MaoX et al.: Multisection 1H magnetic resonance spectroscopic imaging assessment of glioma response to chemotherapy. J. Neurooncol.76(2) , 185–191 (2006).
  • Murphy PS , ViviersL, AbsonC et al.: Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br. J. Cancer90(4) , 781–786 (2004).
  • Jagannathan NR , KumarM, SeenuV et al.: Evaluation of total choline from in vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br. J. Cancer84(8) , 1016–1022 (2001).
  • Leach MO , VerrillM, GlaholmJ et al.: Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed.11(7) , 314–340 (1998).
  • Pucar D , Shukla-DaveA, HricakH et al.: Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology236(2) , 545–553 (2005).
  • Coakley FV , TehHS, QayyumA et al.: Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology233(2) , 441–448 (2004).
  • Griffiths JR , TateAR, HoweFA, StubbsM: Magnetic resonance spectroscopy of cancer-practicalities of multi-centre trials and early results in non-Hodgkin’s lymphoma.Eur. J. Cancer38(16) , 2085–2093 (2002).
  • Schwarz AJ , MaiseyNR, CollinsDJ et al.: Early in vivo detection of metabolic response: a pilot study of 1H MR spectroscopy in extracranial lymphoma and germ cell tumours. Br. J. Radiol.75(900) , 959–966 (2002).
  • Griffin JL , LehtimakiKK, ValonenPK et al.: Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. Cancer Res.63(12) , 3195–3201 (2003).
  • Valonen PK , GriffinJL, LehtimakiKK et al.: High-resolution magic-angle-spinning 1H NMR spectroscopy reveals different responses in choline-containing metabolites upon gene therapy-induced programmed cell death in rat brain glioma. NMR Biomed.18(4) , 252–259 (2005).
  • McPhail LD , ChungYL, MadhuB et al.: Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin. Cancer Res.11(10) , 3705–3713 (2005).
  • Morvan D , DemidemA, PaponJ, De LatourM, MadelmontJC: Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy of intact tumor samples.Cancer Res.62(6) , 1890–1897 (2002).
  • Dyke JP , ZakianKL, SpeesWM et al.: Metabolic response of the CWR22 prostate tumor xenograft after 20 Gy of radiation studied by 1H spectroscopic imaging. Clin. Cancer Res.9(12) , 4529–4536 (2003).
  • Natarajan K , MoriN, ArtemovD, BhujwallaZM: Exposure of human breast cancer cells to the anti-inflammatory agent indomethacin alters choline phospholipid metabolites and Nm23 expression.Neoplasia4(5) , 409–416 (2002).
  • Milkevitch M , ShimH, PilatusU et al.: Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. Biochim. Biophys. Acta1734(1) , 1–12 (2005).
  • Beloueche-Babari M , JacksonLE, Al-Saffar NM et al.: Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Mol. Cancer Ther.5(1) , 187–196 (2006).
  • Beloueche-Babari M , JacksonLE, Al-Saffar NM et al.: Magnetic resonance spectroscopy monitoring of mitogen-activated protein kinase signaling inhibition. Cancer Res.65(8) , 3356–3363 (2005).
  • Chung YL , TroyH, BanerjiU et al.: Magnetic resonance spectroscopic pharmacodynamic markers of the heat shock protein 90 inhibitor 17-allylamino,17-demethoxygeldanamycin (17AAG) in human colon cancer models. J. Natl Cancer Inst.95(21) , 1624–1633 (2003).
  • Cooper WA , BartierWA, RideoutDC, DelikatnyEJ: 1H NMR visible lipids are induced by phosphonium salts and 5-fluorouracil in human breast cancer cells.Magn. Reson. Med.45(6) , 1001–1010 (2001).
  • Glunde K , AckerstaffE, NatarajanK, ArtemovD, BhujwallaZM: Real-time changes in 1H and 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin.Magn. Reson. Med.48(5) , 819–825 (2002).
  • Sterin M , CohenJS, MardorY, BermanE, RingelI: Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study.Cancer Res.61(20) , 7536–7543 (2001).
  • Adebodun F : Phospholipid metabolism and resistance to glucocorticoid-induced apoptosis in a human leukemic cell line: a 31P-NMR study using a phosphonium analog of choline.Cancer Lett.140(1–2) , 189–194 (1999).
  • Viola A , LutzNW, MarocC et al.: Metabolic effects of photodynamically induced apoptosis in an erythroleukemic cell line. A 31P NMR spectroscopic study of Victoria-Blue-BO-sensitized TF-1 cells. Int. J. Cancer85(5) , 733–739 (2000).
  • Kuliszkiewicz-Janus M , BaczynskiS, Jurczyk A: Bone marrow transplantation in the course of hematological malignancies – follow-up study in blood serum by 31P MRS. Med. Sci. Monit.10(8) , CR485–492 (2004).
  • Gottschalk S , AndersonN, HainzC, EckhardtSG, SerkovaNJ: Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.Clin. Cancer Res.10(19) , 6661–6668 (2004).
  • Serkova N , BorosLG: Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.Am. J. Pharmacogenomics5(5) , 293–302 (2005).
  • Yoshimoto M , WakiA, ObataA et al.: Radiolabeled choline as a proliferation marker: comparison with radiolabeled acetate. Nucl. Med. Biol.31(7) , 859–865 (2004).
  • de Molina AR , Banez-CoronelM, Gutierrez R et al.: Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression. Cancer Res.64(18) , 6732–6739 (2004).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.